The molecular basis of the human serum paraoxonase activity polymorphism
- 1 January 1993
- journal article
- Published by Springer Nature in Nature Genetics
- Vol. 3 (1), 73-76
- https://doi.org/10.1038/ng0193-73
Abstract
The organophosphate cholinesterase inhibitor paraoxon is hydrolysed by serum paraoxonase/arylesterase. A genetic polymorphism of paraoxonase (PON) activity which determines high versus low paraoxon hydrolysis in human populations, may determine sensitivity to parathion poisoning. We demonstrate that arginine at position 192 specifies high activity PON whereas a glutamine specifies the low activity variant. Allele-specific probes or restriction enzyme analysis of amplified DNA allow for the genotyping of individuals. PON maps to chromosome 7q21-22, proximal to the cystic fibrosis gene, in agreement with previous genetic linkage studies.Keywords
This publication has 36 references indexed in Scilit:
- Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteinsClinical Genetics, 1991
- Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in ratsToxicology and Applied Pharmacology, 1990
- The human serum paraoxonase—Polymorphism and specificityToxicological & Environmental Chemistry, 1988
- The polymorphism of the human serum paraoxonase†Toxicological & Environmental Chemistry, 1987
- A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7Nature, 1985
- Linkage relationships of paraoxonase (PON) with other markers: indication of PON‐cystic fibrosis syntenyClinical Genetics, 1985
- Genetics of paraoxonaseAnnals of Human Genetics, 1981
- Studies of the acute and long-term oral toxicity of chlorpyrifos (O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl) phosphorothioate)Food and Cosmetics Toxicology, 1974
- Evidence for extrahepatic metabolism of parathion*1, *2Toxicology and Applied Pharmacology, 1972
- Cholinesterase Inhibition by Parathion in vivoNature, 1951